JP2013511554A5 - - Google Patents

Download PDF

Info

Publication number
JP2013511554A5
JP2013511554A5 JP2012540142A JP2012540142A JP2013511554A5 JP 2013511554 A5 JP2013511554 A5 JP 2013511554A5 JP 2012540142 A JP2012540142 A JP 2012540142A JP 2012540142 A JP2012540142 A JP 2012540142A JP 2013511554 A5 JP2013511554 A5 JP 2013511554A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
linear peptide
linear
xaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012540142A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013511554A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/057700 external-priority patent/WO2011063367A1/en
Publication of JP2013511554A publication Critical patent/JP2013511554A/ja
Publication of JP2013511554A5 publication Critical patent/JP2013511554A5/ja
Withdrawn legal-status Critical Current

Links

JP2012540142A 2009-11-23 2010-11-23 メラノコルチン−１受容体特異的線状ペプチド Withdrawn JP2013511554A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26348609P 2009-11-23 2009-11-23
US61/263,486 2009-11-23
PCT/US2010/057700 WO2011063367A1 (en) 2009-11-23 2010-11-23 Melanocortin-1 receptor-specific linear peptides

Publications (2)

Publication Number Publication Date
JP2013511554A JP2013511554A (ja) 2013-04-04
JP2013511554A5 true JP2013511554A5 (OSRAM) 2014-01-23

Family

ID=44060072

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012540142A Withdrawn JP2013511554A (ja) 2009-11-23 2010-11-23 メラノコルチン−１受容体特異的線状ペプチド

Country Status (13)

Country Link
US (3) US8933194B2 (OSRAM)
EP (1) EP2504351A4 (OSRAM)
JP (1) JP2013511554A (OSRAM)
KR (1) KR20120102716A (OSRAM)
CN (1) CN102712674A (OSRAM)
AU (1) AU2010321739A1 (OSRAM)
BR (1) BR112012011780A2 (OSRAM)
CA (1) CA2781405A1 (OSRAM)
EA (1) EA201290295A1 (OSRAM)
IL (1) IL219946A0 (OSRAM)
MX (1) MX2012005859A (OSRAM)
WO (1) WO2011063367A1 (OSRAM)
ZA (1) ZA201203331B (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011063366A1 (en) * 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
IT1404931B1 (it) * 2010-06-11 2013-12-09 Medivis S R L Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
WO2012158960A2 (en) 2011-05-17 2012-11-22 H. Lee Moffitt Cancer Center & Research Institute, Inc. Melanocortin 1 receptor ligands and methods of use
US9290539B2 (en) 2011-05-17 2016-03-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanotropin ligands for skin care
WO2013067309A1 (en) * 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
US9534018B2 (en) 2012-03-13 2017-01-03 Tensive Controls Inc. Melanocortin analogs having enhanced activity and transport
US9821023B2 (en) 2014-06-10 2017-11-21 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of central nervous system (CNS) disorders and mood disorders
US20170022252A1 (en) 2014-06-10 2017-01-26 The Arizona Board Of Regents On Behalf Of The University Of Arizona Novel modulators of melanocortin receptors
US9814755B2 (en) 2014-06-10 2017-11-14 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of depression and anxiety
CN104436159A (zh) * 2014-12-09 2015-03-25 天津医科大学眼科医院 一种新型滴眼液对治疗干眼的用途
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
AU2016298175B2 (en) 2015-07-28 2022-01-06 University Of Iowa Research Foundation Compositions and methods of treating cancer
US10550157B2 (en) 2015-10-16 2020-02-04 Arizona Board Of Regent On Behalf Of The University Of Arizona Compositions and methods for treating central nervous system (CNS) disorders and mood disorders
US11179484B2 (en) 2016-06-24 2021-11-23 University Of Iowa Research Foundation Compositions and methods of treating melanoma
US11591367B2 (en) 2016-10-04 2023-02-28 Dsm Ip Assets B.V. Melanocortin-1-receptor agonists
AU2018215619A1 (en) * 2017-02-01 2019-08-08 Clinuvel Pharmaceuticals Ltd Alpha-MSH analogues used in the treatment of xeroderma pigmentosum
US12364715B2 (en) 2018-02-23 2025-07-22 Enzyvant Therapeutics Gmbh Methods of determining the suitability of cultured thymus tissue for implantation into humans and associated methods of use
AU2019225151A1 (en) 2018-02-23 2020-08-20 Duke University Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants
US11819520B2 (en) * 2018-02-23 2023-11-21 Duke University Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants
US11529335B2 (en) 2020-07-31 2022-12-20 University Of Iowa Research Foundation Compositions and methods for treating cancer
WO2023091689A1 (en) 2021-11-19 2023-05-25 University Of Iowa Research Foundation Combined use of mcr1-directed radiotherapy and immune checkpoint inhibition in the treatment of melanoma
WO2024040167A2 (en) * 2022-08-18 2024-02-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Selective mc4r ligand for treating obesity and cognitive loss
WO2025123055A1 (en) * 2023-12-07 2025-06-12 Endevica Bio, Inc. Non-naturally occurring melanocortin analogs and associated methods for modulating weight gain
WO2025245252A1 (en) * 2024-05-21 2025-11-27 Endevica Bio, Inc. Non-naturally occurring melanocortin receptor agonist analogs for use in pain management and/or substance use disorders

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4731408A (en) 1985-12-20 1988-03-15 Polaroid Corporation Processable conductive polymers
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
US5683981A (en) 1987-05-22 1997-11-04 Competitive Technologies, Inc. Cyclic bridged analogs of α-MSH and methods thereof
EP0292291B1 (en) 1987-05-22 1994-08-10 University Patents, Inc. Linear and cyclic analogs of alpha-msh fragments with extraordinary potency
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US6100048A (en) 1992-04-10 2000-08-08 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
EP0696919B1 (en) 1993-04-05 2002-01-30 Competitive Technologies, Inc. Diagnosis and treatment of erectile dysfunction
US6054556A (en) 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US7396814B2 (en) 1995-06-07 2008-07-08 Palatin Technologies, Inc. Metallopeptide compositions for treatment of sexual dysfunction
CA2158425C (en) 1995-09-15 2003-01-28 Mac E. Hadley Diagnostic and treatment of erectile dysfunction
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
IL118003A0 (en) 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
AU5348098A (en) 1996-12-17 1998-07-15 Quadrant Holdings Cambridge Limited Melanocortins
US5925618A (en) * 1997-03-06 1999-07-20 American Cyanamid Company Peptides useful as somatostatin antagonists
WO1999021571A1 (en) 1997-10-27 1999-05-06 Trega Biosciences, Inc. Melanocortin receptor ligands and methods of using same
US20020099003A1 (en) 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
GB9808229D0 (en) 1998-04-17 1998-06-17 Quadrant Holdings Cambridge Melanocortin receptor ligands
US6284735B1 (en) 1998-04-28 2001-09-04 Lion Bioscience Ag HP-3228 and related peptides to treat sexual dysfunction
US6534503B1 (en) 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
US6265162B1 (en) * 1998-05-05 2001-07-24 Taisei Corporation Method of identifying, detecting and monitoring microorganisms by an aromatic ring hydroxylase dioxygenase gene
SE9801571D0 (sv) 1998-05-05 1998-05-05 Wapharm Ab Melanokortin-1-receptorselektiva föreningar
SE9804614A0 (en) 1998-07-06 2000-01-07 A+ Science Invest Ab New peptides and use thereof
GB9816234D0 (en) 1998-07-24 1998-09-23 William Harvey Research Limite Compounds for use in the treatment of inflammation
CA2622786A1 (en) * 1998-10-16 2000-04-27 Naoto Oku Neovascular-specific peptides
GB9827500D0 (en) 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
EP1140968B9 (en) 1998-12-23 2007-05-09 Merck & Co., Inc. Dna molecules encoding splice variants of the human melanocortin 1 receptor protein
US6887846B2 (en) 1999-03-24 2005-05-03 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
TR200102765T2 (tr) 1999-03-29 2002-05-21 The Procter & Gamble Company Melanokortin reseptör ligandları
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US6699873B1 (en) 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US7049398B1 (en) 1999-08-12 2006-05-23 Palatin Technologies, Inc. Melanocortin metallopeptide constructs, combinatorial libraries and applications
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
WO2001030808A1 (en) 1999-10-27 2001-05-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor-ligand binding
EP1251865A1 (en) 2000-01-18 2002-10-30 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
US6600015B2 (en) 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
IL152116A0 (en) * 2000-04-05 2003-05-29 Vi Technologies Inc Prion-binding ligands and methods of using same
AU2001261363A1 (en) 2000-05-09 2001-11-20 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
GB0012370D0 (en) 2000-05-22 2000-07-12 Quadrant Holdings Cambridge Peptoids
RU2239642C1 (ru) 2000-08-30 2004-11-10 Ф.Хоффманн-Ля Рош Аг Селективные циклопептиды
AU9631301A (en) 2000-09-27 2002-04-08 Procter & Gamble Melanocortin receptor ligands
US20030113263A1 (en) 2001-02-13 2003-06-19 Oregon Health And Sciences University, A Non-Profit Organization Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia
ITMI20011057A1 (it) 2001-05-22 2002-11-22 Bracco Imaging Spa Preparazione ed uso di peptidi ciclici e ramificati e loro deriati marcati come agenti terapeutici agonisti o antagonisti della colecistochi
JP2004534851A (ja) * 2001-07-11 2004-11-18 パラチン テクノロジーズ インク． メラノコルチン受容体に特異的な線状および環状ペプチド
US7345144B2 (en) 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
US7342089B2 (en) 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
WO2003006604A2 (en) 2001-07-12 2003-01-23 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor agonists
US7328344B2 (en) 2001-09-28 2008-02-05 Imagitas, Inc. Authority-neutral certification for multiple-authority PKI environments
FR2835528B1 (fr) 2002-02-01 2004-03-12 Inst Europ Biolog Cellulaire Nouveaux derives peptidiques, leur preparation et leur application therapeutique et cosmetique
US20030186249A1 (en) 2002-04-01 2003-10-02 Zairen Sun Human TARPP genes and polypeptides
US7034004B2 (en) 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
US7618788B2 (en) * 2002-05-10 2009-11-17 Millipore Corporation Proteome epitope tags and methods of use thereof in protein modification analysis
WO2004005318A2 (en) * 2002-07-03 2004-01-15 Bio Science International, Inc. Peptides comprising aromatic d-amino acids and methods of use
WO2004005324A2 (en) 2002-07-09 2004-01-15 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
US7135548B2 (en) 2002-11-14 2006-11-14 Zengen, Inc. Modified α-MSH peptides and derivatives thereof
AU2003290886A1 (en) 2002-11-14 2004-06-15 Zengen, Inc. Modified alpha-msh peptides and derivatives thereof
MXPA05011830A (es) 2003-05-09 2006-01-26 Novo Nordisk As Peptidos para uso en el tratamiento de la obesidad.
EP1625158A2 (en) 2003-05-09 2006-02-15 Novo Nordisk A/S Peptides for use in treating obesity
US20070105759A1 (en) 2003-06-19 2007-05-10 Eli Lilly And Company Melanocortin receptor 4 (mc4) agonists and their uses
US20060293223A1 (en) 2003-06-19 2006-12-28 Eli Lilly And Company Patent Division Uses of melanocortin-3 receptor (mc3r) agonist peptides
US7084111B2 (en) * 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
US20050026948A1 (en) 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
ES2286679T3 (es) 2003-08-20 2007-12-01 Eli Lilly And Company Compuestos, procedimientos y formulaciones para la liberacion oral de un compuesto de peptido de tipo glucagon (glp)-1 o un peptido agonist a del receptor de melanocortina 4 (mc4).
CN100482682C (zh) 2003-09-30 2009-04-29 诺沃挪第克公司 黑皮素受体激动剂
TWI341835B (en) 2003-11-12 2011-05-11 Lg Life Sciences Ltd Melanocortin receptor agonists
NZ547383A (en) 2003-11-24 2009-11-27 Clinuvel Pharmaceuticals Ltd A method of inducing melanogenesis in humans with MC1R variant alleles
WO2005060985A1 (en) 2003-12-10 2005-07-07 Merck & Co., Inc. Inhibition of voluntary ethanol consumption with selective melanocortin 4-receptor agonists
EP1732586A1 (en) 2004-03-29 2006-12-20 Eli Lilly And Company Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continunous infusion
CN1563076A (zh) 2004-04-02 2005-01-12 西南生物工程产业化中试基地有限公司 一种用于治疗性功能障碍的α－MSH类似物及制备方法
US7442693B2 (en) 2004-05-28 2008-10-28 Smithkline Beecham Corporation Diazepine compounds as ligands of the melanocortin 1 and/or 4 receptors
US7553944B2 (en) * 2004-07-21 2009-06-30 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
JP5208504B2 (ja) 2004-08-04 2013-06-12 クリヌベール、ファーマスーティカルズ、リミテッド 対象者でメラニン形成を誘導するための方法
TW200626611A (en) 2004-09-20 2006-08-01 Lonza Ag Peptide cyclisation
AU2005291862B2 (en) 2004-10-08 2010-07-08 Clinuvel Pharmaceuticals Limited Compositions and methods for inducing melanogenesis in a subject
US20060105951A1 (en) 2004-10-25 2006-05-18 Mark Cunningham Melanocortin receptor binding mimetibodies, compositions, methods and uses
JP2008519007A (ja) 2004-11-04 2008-06-05 ノボ ノルディスク アクティーゼルスカブ 肥満症の治療に使用するためのペプチド
WO2006048449A2 (en) 2004-11-04 2006-05-11 Novo Nordisk A/S Mc4r selective peptides and their use in the treatment of obesity
EP1809667A1 (en) 2004-11-04 2007-07-25 Novo Nordisk A/S Peptides for use in the treatment of obesity
US20080280820A1 (en) 2004-11-04 2008-11-13 Ulrich Sensfuss Novel Peptides for Use in the Treatment of Obesity
WO2006060873A1 (en) 2004-12-09 2006-06-15 Prince Henry's Institute Of Medical Research Method for restoring reproductive function
WO2006073771A2 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
WO2006076442A2 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives
WO2006086321A2 (en) * 2005-02-09 2006-08-17 Helix Biomedix Inc. Antimicrobial hexapeptides
WO2006097526A1 (en) 2005-03-17 2006-09-21 Novo Nordisk A/S Compounds for use in the treatment of obesity
EP1885743A1 (en) 2005-05-31 2008-02-13 Yissum Research Development Company, of The Hebrew University of Jerusalem BACKBONE CYCLIZED MELANOCORTIN STIMULATING HORMONE ( alpha S ) ANALOGS
EP3925614A3 (en) 2005-07-08 2022-03-23 Ipsen Pharma Melanocortin receptor ligands
RU2401841C2 (ru) 2005-07-08 2010-10-20 Ипсен Фарма С.А.С. Лиганды рецепторов меланокортинов
CN1709906A (zh) 2005-07-15 2005-12-21 中国科学技术大学 α－促黑激素的环状类似肽及其应用
MX2007016024A (es) 2005-07-18 2008-03-10 Novo Nordisk As Peptidos novedosos para el uso en el tratamiento contra la obesidad.
RS52747B (sr) 2005-08-26 2013-08-30 Abbvie Inc. Terapeutski aktivni analozi alfa-msh
US20080227693A1 (en) 2005-08-29 2008-09-18 Palatin Technologies, Inc. Cyclic Peptide Isolation by Spray Drying
WO2007035474A2 (en) 2005-09-15 2007-03-29 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof
TW200745163A (en) * 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
US8114844B2 (en) 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
AU2006350707A1 (en) 2006-11-08 2008-05-15 Chongxi Yu Transdermal delivery systems of peptides and related compounds
JP2010516654A (ja) 2007-01-18 2010-05-20 ノボ・ノルデイスク・エー／エス 肥満の治療に使用される新規ペプチド
US20100016237A1 (en) 2007-01-18 2010-01-21 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
EP2106406A2 (en) 2007-01-18 2009-10-07 Novo Nordisk A/S Novel peptides for use in the treatment of obesity
WO2008087187A1 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
WO2008087190A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
NZ579056A (en) 2007-03-16 2011-07-29 Pfizer Ltd 5-[3-(3-Hydroxy-phenoxy} -azetidin-1-yl]-5-methyl-2,2-diphenyl-hexanoic acid amide hydrochloride salt
FR2914646A1 (fr) 2007-04-04 2008-10-10 Neorphys Soc Par Actions Simpl Analogues peptidiques des recepteurs des melanocortines
WO2008156677A2 (en) 2007-06-15 2008-12-24 Ipsen Pharma S.A.S. Cyclic peptide melanocortin receptor ligands
EP2197444A1 (en) 2007-09-12 2010-06-23 Glaxo Group Limited Novel combination of therapeutic agents
DK2214693T3 (en) 2007-11-05 2015-11-30 Ipsen Pharma Sas Use of melanocortins in the treatment of insulin sensitivity
AR072072A1 (es) 2008-06-09 2010-08-04 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina para el tratamiento de la obesidad / 669
AU2009257631B2 (en) 2008-06-09 2014-07-24 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2011035205A2 (en) * 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
WO2011063366A1 (en) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides

Similar Documents

Publication Publication Date Title
JP2013511554A5 (OSRAM)
JP2013511553A5 (OSRAM)
JP2013533864A5 (OSRAM)
Ehrlich et al. Cyclization of all-L-pentapeptides by means of 1-hydroxy-7-azabenzotriazole-derived uronium and phosphonium reagents
JP2012529433A5 (OSRAM)
TWI666026B (zh) Ｗｔ１抗原胜肽結合疫苗
RU2014137107A (ru) Пептидомиметические макроциклы
CN101597326B (zh) kahalalide F 及相关化合物
KR101904808B1 (ko) 데가렐릭스 및 이의 중간 화합물의 제조 방법
RU2013103093A (ru) Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкаганов
UA103154C2 (uk) Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його
RU2014148530A (ru) Производные дипептида лизин-глутаминовая кислота
WO2015061720A3 (en) Prostacyclin compounds, compositions and methods of use thereof
AU2013221433A1 (en) Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
JP2015532283A5 (OSRAM)
RU2013102991A (ru) Связанные с дипептидом лекарственные средства
JP2002530430A (ja) Ｃ型肝炎ウイルスｎｓ３プロテアーゼ阻害用の医薬組成物
ES2890676T3 (es) Procedimiento para la producción de D-arginil-2,6-dimetil-L-tirosil-L-lisil-L-fenilalaninamida
JP2009108078A5 (OSRAM)
ES2869430T3 (es) Procedimiento para preparar D-arginil-2,6-dimetil-L-tirosil-L-lisil-L-fenilalaninamida
ES2308539T3 (es) Ciclacion de peptidos.
CA2977720C (en) Use of excess carbodiimide for peptide synthesis at elevated temperatures
JP2006505555A5 (OSRAM)
ES2651265T3 (es) Péptidos sintéticos con un efecto analgésico de tipo no narcótico
EA200400603A1 (ru) Новые пептиды - аналоги гормона высвобождения гормона роста человека